Amnavero.
← Research directory

Research profile

Semaglutide

Semaglutide activates the GLP-1 receptor and influences glucose regulation and appetite.

  • Phase 3 clinical trial
  • Evaluation only
Amnavero Semaglutide research vial concept packaging
Amnavero Semaglutide
Concept packaging

What the research found

In STEP 1, 1,961 adults with obesity or overweight without diabetes received semaglutide or placebo alongside a lifestyle intervention. At 68 weeks, average weight change was −14.9% versus −2.4%.

What remains uncertain

The result applies to the injectable formulation and study population. Different approved semaglutide formulations have their own indications.